DepoMed may sell itself

Reuters reported that DepoMed Inc. (Nasdaq: DEPO) was working with Morgan Stanley to sell itself. Shares of the specialty pharmaceutical soared $3.10 to close at $24.34.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.